Business Parks & Science Centres



Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Argen-X B.V.. (4/14/14). "Press Release: Argen-X Appoints Dr Werner Lanthaler to Its Supervisory Board". Breda & Ghent.

Organisations Organisation Argen-X B.V.
  Today Argen-X N.V. (Argenx) (Euronext + Nasdaq: ARGX)
  Organisation 2 Evotec AG (FSE: EVT, TecDAX)
  Today Evotec SE (FSE: EVT, MDA X/TecDAX)
  Group Evotec (Group)
Products Product therapeutic antibody
  Product 2 drug discovery services
Persons Person Lanthaler, Werner (Evotec AG 200903– CEO before Intercell AG CFO before Austrian Industrial Assoc before McKinsey)
  Person 2 Verhaeghe, Peter (Benaruca 200910)

arGEN-X, a clinical stage human therapeutic antibody company, announces that it has appointed Dr. Werner Lanthaler to its Supervisory Board.

Dr. Lanthaler has an outstanding track record of building and growing life sciences companies. He is currently Chief Executive Officer of Evotec (Frankfurt Stock Exchange: EVT), a role he took in March 2009. Under his leadership Evotec has become one of the leading drug discovery research organisations globally.

Before that, he spent nine years as Chief Financial Officer at Intercell AG (2000-2009). During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine and antibody player.

Dr. Lanthaler played a pivotal role in many of the company's major corporate milestones including the product approval of Intercell's Japanese Encephalitis Vaccine, the company's acquisitions and strategic pharma partnerships, as well as the company's Initial Public Offering in 2005.

From 1998 to 2000, Dr. Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company. He holds a doctorate in Business Administration from Vienna University of Economics and Business, earned a Master's degree from Harvard University, and holds a degree in Psychology.

Peter Verhaeghe, Chairman of the arGEN-X Board said: "I am delighted to welcome Werner to the arGEN-X Supervisory Board. His experience in building successful life sciences companies, and impressive business and corporate development track record will prove highly instrumental in the Company's move to the next level of success."

About arGEN-X

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

For further information, please contact:
Tim Van Hauwermeiren
Chief Executive Officer
T +32 9 243 40 70
Debbie Allen
Senior Director, Business Development
T +44 7974 979479

arGEN-X BVBA (R&D Center)
Technologiepark 30
9052 Zwijnaarde

Mark Swallow
David Dible
Citigate Dewe Rogerson
T +44 207 282 2949

Mark Swallow PhD

DDI: +44 (0)20 7282 2948
Switchboard: +44 (0)20 7638 9571
Mob: +44 (0)7903 737703

Citigate Dewe Rogerson
3 London Wall Buildings
London EC2M 5SY
United Kingdom

Record changed: 2017-04-02


Picture [LSE] – The Business Web Portal 600x60px

More documents for Argenx (Argen-X) (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica iito 600x60px

» top